Evidence map›Paper›PMID 40358833›Full record

Trial reportAnnals of nuclear medicine2025

A first-in-man PET study of 2-amino-[3-

Kentaro Tamura, Atsushi B Tsuji, Ryuichi Nishii, Kotaro Tani, Hiroki Hashimoto, Kazunori Kawamura, Ming-Rong Zhang, Takamasa Maeda, Kana Yamazaki, Tatsuya Higashi

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kentaro TamuraDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba City, Chiba, 263-8555, Japan.
Atsushi B TsujiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba City, Chiba, 263-8555, Japan.
Ryuichi NishiiDepartment of Integrated Health Sciences, Graduate School of Medicine, Nagoya University, 1-1-20 Daiko Minami, Higashi-ku, Nagoya, 461-8673, Japan.
Kotaro TaniDepartment of Radiation Measurement and Dose Assessment, Institute for Radiological Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba City, Chiba, 263-8555, Japan.
Hiroki HashimotoDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba City, Chiba, 263-8555, Japan.
Kazunori KawamuraDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba City, Chiba, 263-8555, Japan.
Ming-Rong ZhangDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba City, Chiba, 263-8555, Japan.
Takamasa MaedaDepartment of Medical Technology, QST Hospital, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba City, Chiba, 263-8555, Japan.
Kana YamazakiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba City, Chiba, 263-8555, Japan.
Tatsuya HigashiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba City, Chiba, 263-8555, Japan. higashi.tatsuya@qst.go.jp.ORCID http://orcid.org/0000-0002-8338-4737

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis first-in-human study aimed to assess the biodistribution, radiation dosimetry, and safety of the novel PET tracer [3-

methodsSix healthy male participants underwent whole-body PET/CT scans following a rapid intravenous bolus of [3-

resultsHigh tracer uptake was observed in the salivary glands, pancreas, kidneys, and liver, whereas uptake in the brain and skeletal muscles remained low. The principal route of excretion was via the urinary tract. The effective dose was 5.1 µSv/MBq, corresponding to 1.9 mSv for 370 MBq injection comparable to other 11C-labeled amino acid tracers. No adverse events or significant changes in clinical assessments were noted.

conclusionsThis first-in-man evaluation of [3-

Indexed as

Aminoisobutyric AcidsCarbon RadioisotopesPositron Emission Tomography Computed TomographyAdultBiological TransportHealthy VolunteersHumansMaleRadiometryTissue DistributionWhole Body ImagingYoung AdultAminoisobutyric AcidsCarbon-11Carbon RadioisotopesAmino acid transporterBiodistributionIDACNormal healthy volunteersPositron emission tomographyRadiation dosimetry

Identifiers

PMID40358833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.